Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases

Abstract

Rituximab is beneficial in the management of refractory PV, resulting in clinical remission and a steroid-sparing effect. Further study needs to examine rituximab dosage and scheduling as well as its place within the treatment algorithm.

Treatment outcomes in a cohort of patients with mucosal‐predominant pemphigus vulgaris

“…32 This high success rate has been confirmed in a number of other studies. [33][34][35][36][37][38][39] A literature summary by Feldman and Ahmed in 2011 found an overall complete remission rate of 66%, in 153 PV patients treated with rituximab, 40 values similar to those reported in our observational cohort. Unfortunately, a major limitation to the more widespread use of rituximab in PV remains its expense; Figure 2 Mean daily prednisolone doses while on treatment for azathioprine (Aza), mycophenolate (MMF) or after one (Ritux1), two (Ritux2) or three (Ritux3) doses of rituximab.…”

“…reported that 36/42 pemphigus patients achieved complete remission 6 months after a course of rituximab, 50% of whom remained in remission during a follow‐up period of 12 to 59 months . This high success rate has been confirmed in a number of other studies . A literature summary by Feldman and Ahmed in 2011 found an overall complete remission rate of 66%, in 153 PV patients treated with rituximab, values similar to those reported in our observational cohort.…”

Pemphigus vulgaris and laser therapy: Crucial role of dentists

“…However, corticosteroids are limited by various time and dose dependent adverse effects. Less studied, emerging therapies include intravenous immunoglobulin, plasmapheresis, immunoadsorption, extracorporeal photochemotherapy, cholinergic agonists, rituximab, anti-CD20 monoclonal antibody therapy, tumor necrosis factor-α (TNF-α) inhibitors and other experimental therapies such as Desmoglein-3 peptides [10][11][12]. Unfortunately, steroid-sparing agents are often associated with significant toxicity.…”

Efficacy and safety of rituximab in the treatment of refractory pemfigus vulgaris

“…Baum ve ark. 'nın 18 dirençli PV hastasında lenfoma protokolü ile uygulanan ritüksimab tedavisi ile %61,1 tam remisyon, %11,1 parsiyel remisyon sağlanmış, ortalama izlem süresi 9 ay olan çalışmada relaps ortalama 9. ayda %33,3 saptanmıştır 23 . 2013 yılında yayınlanan Lehsem ve ark.…”